Kelonia Therapeutics has made a remarkable recovery, evolving from a challenging phase to achieving a valuation of $3 billion.
In related news, BioAge is concentrating its efforts on inflammation, indicating a strategic direction within the biotech landscape.
These developments reflect ongoing shifts and opportunities in the biotech industry, as companies navigate challenges and pursue growth.